Orchestra BioMed
Update in progressOBIO (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Orchestra BioMed Holdings, Inc. is a U.S. biomedical company focused on cardiovascular therapies and related devices. Lead programs include AVIM, a bioelectronic therapy aimed at quickly and durably lowering blood pressure; Virtue Sirolimus AngioInfusion Balloon for atherosclerotic disease; Cardiac Neuromodulation Therapy and CNT-HF for heart failure; and FreeHold and Pure-Vu systems for minimally invasive care. It collaborates with Medtronic on AVIM and with Terumo on Virtue SAB. Founded 2018, based in New Hope, PA.
Company score
- Sentiment
- 0.38
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.24
- Governance
- 0.11
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.09
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.24
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationUnited States
- CEOMr. David P. Hochman
- Founded2018
- Employees86
- Websitewww.orchestrabiomed.com
Identifiers
- ISINUS68572M1062
- FIGIBBG00W5FR2T5
- CUSIP68572M106
- CIK0001814114